Training Grant in Cancer Biology

描述（由申请人提供）：佛罗里达大学在癌症研究和癌症患者护理方面有着悠久而富有成效的历史。我们寻求竞争性地更新我们的T32癌症生物学培训补助金（CBTG），目前已连续30年获得资助。癌症生物学培训计划的总体目标是通过在实验室提供专家和全面的指导，为我们的博士后和博士前学员成功的癌症研究事业做好准备。已经做了一些重大的改变。其中包括佛罗里达大学尚兹癌症中心（UFSCC）的持续发展，并招募了更多的癌症研究人员，这些人员已成为CBTG教师的成员。此外，一个新的癌症和遗传学研究大楼的建设，增加了28.4万平方米。新落成的基础及转化研究中心面积约1平方米，现已落成，并将于2006年6月投入使用。该建筑是佛罗里达大学校园内最大的研究建筑，由UFSCC和UF遗传学研究所的研究人员共享，从而汇集并形成了一个更深入的癌症研究人员的临界质量。癌症生物学培训计划概述在这个竞争性继续申请（即31-35年）有教师的专业知识，基础设施，资源和癌症为重点的研究机会，继续提供一个优秀的培训环境。特别强调的是培养医学博士，医学博士/博士或博士后，以及博士预科博士或医学博士/博士候选人，他们计划从事肿瘤学和癌症研究的学术研究，包括基础研究和转化研究。我们的项目展示了学员们的杰出成就。大多数人仍然在学术岗位上，并为癌症患者发现和发展新的治疗方法、诊断或预防措施做出了新知识的贡献。此外，我们继续积极鼓励和招聘多元化的学员。最后，为了确保我们对基础科学发现的临床转化的承诺，并利用NIH承认双重PI的新政策，Maureen Goodenow博士已被现任PI W. Stratford May, Jr., m.d., Ph.D.任命为T32癌症生物学培训基金的共同PI。

DESCRIPTION (provided by applicant): The University of Florida has a long and productive history in cancer research and care of cancer patients. We seek to competitively renew our T32 Cancer Biology Training Grant, (CBTG) currently in its 30th consecutive year of funding. The overall goal of the Cancer Biology Training Program is to prepare our post- and pre-doctoral trainees for a successful cancer research career by providing expert and comprehensive mentoring in the laboratory. Some significant changes have been made. These include the continued development of the University of Florida Shands Cancer Center (UFSCC) with recruitment of additional cancer focused research faculty who have become members of the CBTG faculty. In addition, the construction of a new Cancer and Genetics Research Building that adds 284,000 sq. ft. of new basic and translational research space is now complete and available for occupancy in June, 2006. The building is the largest research building on the campus of the University of Florida and is shared by investigators in the UFSCC and UF Genetics Institute, thus bringing together and forging a deeper critical mass of cancer-focused researchers. The Cancer Biology Training Program outlined in this competitive continuation application (i.e., years 31-35) has the faculty expertise, infrastructure, resources and cancer- focused research opportunities to continue to provide an outstanding training environment. A special emphasis is on the training of MD, MD/PhD or PhD post-doctoral, as well as pre-doctoral PhD or MD/PhD candidates, who plan to pursue careers in academic oncology and cancer research that involve basic and translational studies. Our program has demonstrated outstanding success of its trainees. Most have remained in academic positions and have made contributions of new knowledge that lead to discovery and development of novel treatments, diagnosis or prevention measures for patients with cancer. In addition, we continue to actively encourage and recruit diversity among our trainees. Finally, to help ensure our commitment to the clinical-translation of basic science discoveries and to take advantage of the NIH's new policy of recognizing dual PIs, Maureen Goodenow, Ph.D. has been appointed Co-PI of the T32 Training Grant in Cancer Biology by the current PI, W. Stratford May, Jr., M.D., Ph.D.